Literature DB >> 7857937

Specific binding of the biradical analog of neocarzinostatin chromophore to bulged DNA: implications for thiol-independent cleavage.

C F Yang1, A Stassinopoulos, I H Goldberg.   

Abstract

The enediyne anticancer antibiotic neocarzinostatin chromophore generates a single, site-specific break at a bulge in DNA in a thiol-independent reaction, involving intramolecular drug activation under general base catalysis [Kappen, L. S., & Goldberg, I. H. (1993) Biochemistry 32, 13138-13145]. As part of an effort to elucidate the three-dimensional structure of the active complex formed between the labile drug and bulged DNA, we have studied the binding of stable drug products generated in the course of the cleavage reaction with oligodeoxynucleotides containing the bulged structure. By use of fluorescence quenching, we have found that one drug product, which is also formed in the absence of bulged DNA and most closely resembles the biradical intermediate in the cleavage reaction, specifically binds bulged DNA with a Kd in the low micromolar range and competitively inhibits the cleavage reaction. Other drug products, including one formed only in the presence of bulged DNA, fail to bind to the bulged DNA. Implications of these results for the proposed mechanism of bulge-specific cleavage and for the role of the DNA bulge in generating a unique drug product are discussed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7857937     DOI: 10.1021/bi00007a022

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  Probing DNA bulges with designed helical spirocyclic molecules.

Authors:  Lizzy S Kappen; Yiqing Lin; Graham B Jones; Irving H Goldberg
Journal:  Biochemistry       Date:  2007-01-16       Impact factor: 3.162

2.  Solution structure of a designed spirocyclic helical ligand binding at a two-base bulge site in DNA.

Authors:  Na Zhang; Yiqing Lin; Ziwei Xiao; Graham B Jones; Irving H Goldberg
Journal:  Biochemistry       Date:  2007-03-28       Impact factor: 3.162

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.